

Burden Hour Statement: This form is estimated to take 2-6 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Please type a plus sign (+) inside this box ☒

Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information from which it collects a fee if it does not display this notice.

PTO/SB/08 (10-01)
Approved for use through 10/1/01 OMB 0501-0001

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete If Known

Applicant Number	10/002,690
Filing Date	12/05/2001
First Named Inventor	Phillip Cavanaugh
Group Art Unit	1645
Examiner Name	Ja-Na Hines
Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the book, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	1*
JH	1	LAGRANGE, J.L. et al., "Demonstration and characterization of EGF receptors in cancer of the uterine cervix", <i>Bull Cancer</i> , 1993, 80:219-224. <u>ABS</u>	
	2	INOUE, T. et al., "Differences in transferrin response and members of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials", <i>Journal of Cellular Physiology</i> , 1993, 156:212-217.	
	3	CAVANAUGH, P.G., and NICOLSON, O.L., "The selection of a metastatic rat mammary adenocarcinoma cell line from a low metastatic parental population by <i>in vitro</i> process based on cellular ability to proliferate in response to transferrin", <i>Journal of Cellular Physiology</i> , 174, 48-57, 1998.	
	4	CAVANAUGH, P.G., et al., "Transferrin receptor overexpression enhances transferrin responsiveness and the metastatic growth of a rat mammary adenocarcinoma cell line", <i>Breast Cancer Research and Treatment</i> , 56, 203-217, 1999.	
	5	GORDON, L.L., "Scatchard analysis of fluorescent concanavalin A binding to lymphocytes", <i>Cytometry</i> , 1995, 20, 238-244.	
	6	PALUPI, N.S. et al., "Bovine beta-2-microglobulin receptors on transformed mammalian cells (hybridomas MARK-1): characterization by flow cytometry", <i>J Biotechnol</i> , 2000, 78, 171-184.	
	7	SAMUEL D. et al., "A sensitive method of detecting proteins on dot and Western blots using a monoclonal antibody to FITC", <i>J Immunol Methods</i> , 1988, 107, 217-224.	
	8	HASELBACK, A. et al., "Structural characterization of glycoprotein carbohydrate chains by using digoxigenin-labeled lectins on blot", <i>Analytical Biochemistry</i> , 1990, 191, 23-30.	
	9	HASELBACK, A. and HOSEL, W., "Detection of proteins and glycoproteins on western blot", in "Nonradioactive labeling and detection of biomolecules", KESLER, C., ed., 1992, 297-299, Springer-Verlag, Berlin.	
	10	ZHANG, G., et al., "Early detection of apoptosis using a fluorescent conjugate of annexin V", <i>Biotechniques</i> , 1997, 23, 525-531.	
✓	11	LE GALL M., et al., "The p42/p44 MAP kinase pathway prevents apoptosis induced by anchorage and serum removal", <i>Mol Biol Cell</i> , 2000, 11, 1103-1112.	

Examiner Signature	/Ja-Na Hines/ (09/14/2006)	Date Considered	09/14/2006
--------------------	----------------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in accordance with MPEP 808. Draw line through citation if not in accordance and not considered. Include copy of this form with final communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Search Fee Statement: This form is estimated to take 2.0 hours to complete. There will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEE OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Policy, Washington, DC 20231.**

Notice of References Cited	Application/Control No. 10/002,690	Applicant(s)/Patent Under Reexamination CAVANAUGH, PHILIP GERARD	
	Examiner Ja-Na Hines	Art Unit 1645	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Cavanaugh et al. 1998. J. of Cell. Physio. 174:48-57.
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.